Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus

R. C. Newton, J. L. Jorizzo, Alvin Jr Solomon, R. L. Sanchez, J. C. Daniels, J. D. Bell, T. Cavallo

Research output: Contribution to journalArticle

Abstract

Eight of ten patients with chronic or subacute cutaneous lupus erythematosus completed 16 weeks of oral isotretinoin therapy (80 mg/day). All eight patients noted an excellent clinical response without significant side effects. (Two patients did not return to initial two-week follow-up). Peripheral blood B- and T-cell counts were unaffected by therapy. Therapy was associated with resolution of routine histopathologic abnormalities, conversion of abnormal lesional direct immunofluorescence microscopy to normal, normalization of the epidermis on electron microscopy, and reduction of all T cells near the dermoepidermal junction without change in ratio of T-helper/inducer cells to T-suppressor/cytotoxic cells. Isotretinoin is a clinically effective short-term therapy for chronic or possibly for subacute cutaneous lupus erythematosus. The primary mechanism of action remains unestablished.

Original languageEnglish (US)
Pages (from-to)170-176
Number of pages7
JournalArchives of Dermatology
Volume122
Issue number2
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Cutaneous Lupus Erythematosus
Discoid Lupus Erythematosus
Isotretinoin
T-Lymphocytes
Direct Fluorescent Antibody Technique
Therapeutics
Helper-Inducer T-Lymphocytes
Fluorescence Microscopy
Epidermis
Electron Microscopy
Cell Count

ASJC Scopus subject areas

  • Dermatology

Cite this

Newton, R. C., Jorizzo, J. L., Solomon, A. J., Sanchez, R. L., Daniels, J. C., Bell, J. D., & Cavallo, T. (1986). Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Archives of Dermatology, 122(2), 170-176. https://doi.org/10.1001/archderm.122.2.170

Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. / Newton, R. C.; Jorizzo, J. L.; Solomon, Alvin Jr; Sanchez, R. L.; Daniels, J. C.; Bell, J. D.; Cavallo, T.

In: Archives of Dermatology, Vol. 122, No. 2, 1986, p. 170-176.

Research output: Contribution to journalArticle

Newton, RC, Jorizzo, JL, Solomon, AJ, Sanchez, RL, Daniels, JC, Bell, JD & Cavallo, T 1986, 'Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus', Archives of Dermatology, vol. 122, no. 2, pp. 170-176. https://doi.org/10.1001/archderm.122.2.170
Newton, R. C. ; Jorizzo, J. L. ; Solomon, Alvin Jr ; Sanchez, R. L. ; Daniels, J. C. ; Bell, J. D. ; Cavallo, T. / Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. In: Archives of Dermatology. 1986 ; Vol. 122, No. 2. pp. 170-176.
@article{2eab84bd62db45ca999ef173cf3ac1fe,
title = "Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus",
abstract = "Eight of ten patients with chronic or subacute cutaneous lupus erythematosus completed 16 weeks of oral isotretinoin therapy (80 mg/day). All eight patients noted an excellent clinical response without significant side effects. (Two patients did not return to initial two-week follow-up). Peripheral blood B- and T-cell counts were unaffected by therapy. Therapy was associated with resolution of routine histopathologic abnormalities, conversion of abnormal lesional direct immunofluorescence microscopy to normal, normalization of the epidermis on electron microscopy, and reduction of all T cells near the dermoepidermal junction without change in ratio of T-helper/inducer cells to T-suppressor/cytotoxic cells. Isotretinoin is a clinically effective short-term therapy for chronic or possibly for subacute cutaneous lupus erythematosus. The primary mechanism of action remains unestablished.",
author = "Newton, {R. C.} and Jorizzo, {J. L.} and Solomon, {Alvin Jr} and Sanchez, {R. L.} and Daniels, {J. C.} and Bell, {J. D.} and T. Cavallo",
year = "1986",
doi = "10.1001/archderm.122.2.170",
language = "English (US)",
volume = "122",
pages = "170--176",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus

AU - Newton, R. C.

AU - Jorizzo, J. L.

AU - Solomon, Alvin Jr

AU - Sanchez, R. L.

AU - Daniels, J. C.

AU - Bell, J. D.

AU - Cavallo, T.

PY - 1986

Y1 - 1986

N2 - Eight of ten patients with chronic or subacute cutaneous lupus erythematosus completed 16 weeks of oral isotretinoin therapy (80 mg/day). All eight patients noted an excellent clinical response without significant side effects. (Two patients did not return to initial two-week follow-up). Peripheral blood B- and T-cell counts were unaffected by therapy. Therapy was associated with resolution of routine histopathologic abnormalities, conversion of abnormal lesional direct immunofluorescence microscopy to normal, normalization of the epidermis on electron microscopy, and reduction of all T cells near the dermoepidermal junction without change in ratio of T-helper/inducer cells to T-suppressor/cytotoxic cells. Isotretinoin is a clinically effective short-term therapy for chronic or possibly for subacute cutaneous lupus erythematosus. The primary mechanism of action remains unestablished.

AB - Eight of ten patients with chronic or subacute cutaneous lupus erythematosus completed 16 weeks of oral isotretinoin therapy (80 mg/day). All eight patients noted an excellent clinical response without significant side effects. (Two patients did not return to initial two-week follow-up). Peripheral blood B- and T-cell counts were unaffected by therapy. Therapy was associated with resolution of routine histopathologic abnormalities, conversion of abnormal lesional direct immunofluorescence microscopy to normal, normalization of the epidermis on electron microscopy, and reduction of all T cells near the dermoepidermal junction without change in ratio of T-helper/inducer cells to T-suppressor/cytotoxic cells. Isotretinoin is a clinically effective short-term therapy for chronic or possibly for subacute cutaneous lupus erythematosus. The primary mechanism of action remains unestablished.

UR - http://www.scopus.com/inward/record.url?scp=0022610283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022610283&partnerID=8YFLogxK

U2 - 10.1001/archderm.122.2.170

DO - 10.1001/archderm.122.2.170

M3 - Article

C2 - 3511858

VL - 122

SP - 170

EP - 176

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 2

ER -